

ANSTO's technology commercialisation successes include Platinum Therapies.
Platinum based chemotherapeutic agents are used in the treatment of cancers. ANSTO patent technology involves the rapid and reliable synthetic method for platinum-based radiopharmaceuticals applicable to first, second and third generation platinum agents that includes 195mPt Cisplatin and 195mPt Carboplatin.
Injection of an radiopharmaceutical imaging agent
Commercial status:
Clinical studies commencing in 2010
Inventor:
Suzanne Smith
ANSTO Business Development contact:
Joy Woods (+61 2 9717 9009)